The emergence of SARS-CoV-2 variants threatens efforts to control the COVID-19 pandemic. At present, the global spread of the Delta (B.1.617.2) variant is responsible for a rapid increase in COVID-19 cases and hospitalizations in many countries. The variant evades neutralizing antibodies and is believed to be more transmissible and pathogenic [1,2,3,4]. Neutralizing antibodies are produced upon vaccination or infection; for the latter, it is known that levels correlate with the duration and severity of clinical symptoms . Antibody evasion is caused by mutations in the viral spike protein, several of which are located in the receptor-binding domain, which is the key target of the neutralizing antibody response.
Recently, sublineages of the Delta (B.1.617.2) variant have emerged, termed Delta Plus , which are purported to be more transmissible. These viruses harbor the K417N mutation (Fig. 1A, B), which is also found in the Beta (B.1.351) variant and is associated with neutralization resistance . Furthermore, another sublineage of the Delta variant was observed in Vietnam and might contribute to a recent surge in cases. This variant (provisionally termed Delta-V) is reported to contain mutations found in the S protein of the Alpha (B.1.1.7) variant, and it was initially proposed to be a hybrid virus. Indeed, Delta variant sequences from Vietnam and many other countries with deletions at positions H67, V70, and/or Y144 (Fig. 1A, B), also found in spike of the Alpha (B.1.1.7) variant, have been deposited in the GISAID (Global Initiative on Sharing All Influenza Data) database. Thus, sublineages of the Delta variant have arisen that might have altered biological properties and may present an increased threat to human health.
We sought to determine whether Delta Plus and Delta-V differ from the Delta variant regarding cell entry and neutralization sensitivity by using rhabdoviral pseudotypes, which are adequate models for cell entry of SARS-CoV-2, and previously described monoclonal antibodies and sera/plasma from infected or BNT162b2/Comirnaty vaccinated individuals [8, 9]. The Delta Plus and Delta-V variants entered the Vero and 293T kidney-derived cell lines with similar efficiency as the Delta variant and WT virus (Wuhan/Hu-1/2019 isolate with the D614G mutation) (Fig. 1C). Furthermore, entry of the Delta variant into the lung- and colon-derived cell lines Calu-3 and Caco-2 was enhanced, in keeping with a previous study ; an increase in entry efficiency was also observed for the Delta Plus and Delta-V variants (Fig. 1C). The Delta variant was resistant to neutralization by the monoclonal antibody bamlanivimab, whereas Delta Plus was resistant to both bamlanivimab and etesevimab (Fig. 1D), with resistance to the latter most likely due to the K417N mutation . Finally, the Delta variant showed reduced neutralization by antibodies induced by SARS-CoV-2 infection and BNT162b2/Comirnaty vaccination, in agreement with previous findings and in line with data for its parental lineage B.1.617 [2,3,4, 8, 9, 11] and neutralization of the Delta Plus and Delta-V variants was reduced to similar levels (Fig. 1E, F).
Our results reveal no appreciable differences between host cell entry and neutralization sensitivity of the Delta variant and its sublineages, with the notable exception of the Delta Plus variant being resistant to both bamlanivimab and etesevimab, which are used in cocktails for COVID-19 treatment. Although T-cell responses were not analyzed in the present study and confirmation of the data using authentic virus and primary cells is pending, our results suggest that neither the Delta Plus nor the Delta-V variant is associated with an increased threat to convalescent or BNT162b2/Comirnaty vaccinated patients compared to the founder virus. Finally, it is noteworthy that heterologous ChAdOx1 nCov-19/BNT162b2 vaccination might provide particularly robust protection against these viruses .
Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021;26:2100509.
Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021;184:4220–36.
Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596:273–5.
Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397:2331–3.
Bosnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol. 2021;18:936–44.
Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 16. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1001359/Variants_of_Concern_VOC_Technical_Briefing_16.pdf.
Zhang Q, Ju B, Ge J, Chan JF, Cheng L, Wang R, et al. Potent and protective IGHV3-53/3-66 public antibodies and their shared escape mutant on the spike of SARS-CoV-2. Nat Commun. 2021;12:4210.
Arora P, Kempf A, Nehlmeier I, Sidarovich A, Krüger N, Graichen L, et al. Increased lung cell entry of B.1.617.2 and evasion of antibodies induced by infection and BNT162b2 vaccination. bioRxiv. 2021. https://doi.org/10.1101/2021.06.23.449568.
Hoffmann M, Hofmann-Winkler H, Kruger N, Kempf A, Nehlmeier I, Graichen L, et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 2021;36:109415.
Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371:850–4.
Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–80.
Hammerschmidt SI, Bosnjak B, Bernhardt G, Friedrichsen M, Ravens I, Dopfer-Jablonka A, et al. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cell Mol Immunol. 2021;18:2455–6.
SP acknowledges funding by BMBF (01KI2006D, 01KI20328A, 01KI20396, and 01KX2021), the Ministry for Science and Culture of Lower Saxony (14-76103-184, MWK HZI COVID-19) and the German Research Foundation (DFG; PO 716/11-1, PO 716/14-1). MSW received unrestricted funding from Sartorius AG, Lung Research. HMJ received funding from BMBF (01KI2043, NaFoUniMedCovid19-COVIM: 01KX2021), Bavarian State Ministry for Science and the Arts and Deutsche Forschungsgemeinschaft (DFG) through the research training groups RTG1660 and TRR130. G.B. acknowledges funding from the German Center for Infection Research (grant no 80018019238).
Open Access funding enabled and organized by Projekt DEAL.
The authors declare no competing interests.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Arora, P., Kempf, A., Nehlmeier, I. et al. Delta variant (B.1.617.2) sublineages do not show increased neutralization resistance. Cell Mol Immunol 18, 2557–2559 (2021). https://doi.org/10.1038/s41423-021-00772-y
This article is cited by
Structural biology of SARS-CoV-2: open the door for novel therapies
Signal Transduction and Targeted Therapy (2022)